Documenting a Significant Difference: What a 503A Prescription Needs

Why this question is coming up now

Compounding compliance has been in the news this month, and one theme runs through the commentary: for a 503A pharmacy, what matters is not how many prescriptions a program sends, but whether each one is truly written for the patient named on it. For clinics and telehealth programs, that comes down to what is on the prescription.

The patient-specific rule in plain terms

Section 503A of the federal Food, Drug, and Cosmetic Act allows a licensed pharmacy to compound a medication for an identified individual patient, based on a valid prescription from a licensed prescriber. Each preparation is made for the person named on the prescription, at the strength the prescriber writes. Our explainer on what a 503A pharmacy is covers the wider framework.

When a commercially available product exists

The same section limits the compounding of preparations that are essentially copies of a commercially available drug product. FDA's January 2018 guidance on essential copies explains that a compounded preparation is not treated as a copy when the prescriber determines that a change made for an identified patient produces a significant difference for that patient, compared with the commercial product.

The guidance says that determination should be documented on the prescription. No particular format is required, as long as the prescription shows the change and the difference it makes for the patient. Two of the examples it gives:

• "No Dye X, patient allergy," where the commercial product contains that dye.
• "Liquid form, patient can't swallow tablet," where the commercial product is a tablet.

A prescription that lists only the patient's name and the formulation is not enough on its own. The guidance also notes that factors such as a lower price do not count as a significant difference.

What this means for your prescribers

• Write the change and the reason for this patient. A short, specific note is what the guidance describes.
• Keep it individual. The determination is about one patient, so identical wording pasted into every prescription does not show that each patient was considered. Set up your prescribing workflow so the note reflects the person being treated.
• Know when it applies. Many preparations clinics order from a compounding pharmacy have no commercially manufactured equivalent at all, such as estriol or Bi-Est. The question arises when a manufactured product with the same active ingredient, in the same or a similar strength and by the same route, already exists.
• Expect a call if the note is missing. The guidance allows the pharmacy to confirm the determination with the prescriber and record it on the prescription, along with the date of that conversation.

How we work with clinic programs

ProCompounding is a PCAB-accredited 503A compounding pharmacy in Johnson City, Tennessee, licensed in all 50 states and the District of Columbia. A pharmacist reviews every formulation before it is made, and during onboarding we review your prescribing workflow with you, so prescriptions reach us complete. Prescriptions can arrive by direct API connection, e-prescribing or our provider portal.

A documented sensitivity is one of the most common reasons a prescriber orders a compounded version of a medication. Our page on dye-free compounded medications describes the bases and options we prepare, and our page on compounding fulfillment for telehealth clinics explains how a program works with us. When your team is ready, start clinic onboarding and tell us about your program.

Compounded preparations are not reviewed or approved by the FDA for safety or efficacy. This article is general information for clinics and is not legal or medical advice.